HIV
Conference Coverage
Being HIV positive increases risk of death from COVID-19
For patients below the age of 70, the risk of mortality was double in people with HIV.
Conference Coverage
Switch to integrase inhibitor regimen safe and effective
Forty-eight weeks after the switch, virologic suppression was maintained among 94.3% of those on an integrase inhibitor–based regimen.
Conference Coverage
Islatravir + doravirine maintains HIV viral suppression
ISL+DOR appeared to be “well tolerated,” according to the investigators.
Supplements
Infectious Diseases Board Review: Simplifying or Switching Antiretroviral Therapy in Treatment-Experienced Adults Living With HIV
Conference Coverage
Weight gain persists as HIV-treatment issue
Conference Coverage
Easy access to PrEP reduces rates of HIV acquisition
“We haven’t really seen PrEP being scaled up and offered at such a broad level in communities,” Koss said during AIDS 2020.
From the Journals
HSCT or systemic treatment should be offered to HIV+ patients with lymphoma
Conference Coverage
Injection beats pill for long-lasting HIV prevention
The findings “could transform the HIV prevention landscape for so many people,” said Megan Coleman, DNP.
Conference Coverage
Neural tube defect risk from dolutegravir drops as clinical experience grows
A troubling link between the top HIV drug dolutegravir and neural tube defects, first reported in 2018, now seems much less dangerous.
Conference Coverage
Brazilian patient in HIV remission, negative antibody test
The 35-year-old Brazilian man participated in a trial in which he received an intensified antiretroviral regimen plus supplemental vitamin B3...
News from the FDA/CDC
FDA OKs first-in-class HIV therapy for patients with few options
“The availability of new classes of antiretroviral drugs is critical for heavily treatment-experienced patients living with multidrug resistant...